Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15257837 | 0.85 | HRH4 (0.49) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL13159147 | 0.85 | RAB9A (0.52) | MAPTNPC1LMNAL3MBTL1RAB9A | |
| SCHEMBL13159141 | 0.82 | RAB9A (0.68) | MAPTNPC1LMNARAB9AALDH1A1 | |
| SCHEMBL6126431 | 0.82 | SCN4A (0.48) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL18091084 | 0.78 | KDM4E (0.47) | MAPTNPC1L3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL2962364 | 0.77 | MIF (0.52) | MAPTNPC1LMNAL3MBTL1RAB9A | |
| SCHEMBL13159114 | 0.75 | DTYMK (0.53) | MAPTNPC1LMNARAB9A | |
| SCHEMBL13159122 | 0.70 | MIF (0.40) | MAPTNPC1LMNAL3MBTL1RAB9A | |
| SCHEMBL13159118 | 0.69 | LMNA (0.44) | MAPTLMNAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18641269 | 0.68 | MAPT (0.77) | MAPTNPC1LMNAL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | MAPT 4744/4885NPC1 1639/4885LMNA 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.